Clinical Trial News and Research

RSS
Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

EMA COMP grants orphan medicinal product designation for Raptor's DR Cysteamine for cystinosis

EMA COMP grants orphan medicinal product designation for Raptor's DR Cysteamine for cystinosis

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer

Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer

Project ideas needed from worldwide Alzheimer Disease research community

Project ideas needed from worldwide Alzheimer Disease research community

ACRO unveils survey findings on decline in physician participation in clinical research

ACRO unveils survey findings on decline in physician participation in clinical research

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

Pediatric oncologist describes current state of science in combating neuroblastoma

Pediatric oncologist describes current state of science in combating neuroblastoma

FDA grants HeartWare approval for IDE destination therapy study of Ventricular Assist System

FDA grants HeartWare approval for IDE destination therapy study of Ventricular Assist System

ConvaTec presents Vitala Continence Control Device Phase 2 data at 2010 WOCN/WCET joint conference

ConvaTec presents Vitala Continence Control Device Phase 2 data at 2010 WOCN/WCET joint conference

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Medidata Solutions launches new RTSM solution for clinical research sponsors, sites

Medidata Solutions launches new RTSM solution for clinical research sponsors, sites

Study evaluates correlation between EverOn system and detection of patient deterioration in hospitals

Study evaluates correlation between EverOn system and detection of patient deterioration in hospitals

BioClinica eClinical Technology Suite and BIOP to be showcased at DIA Annual Meeting

BioClinica eClinical Technology Suite and BIOP to be showcased at DIA Annual Meeting

Endosense awards DATATRAK first two EFFICAS studies

Endosense awards DATATRAK first two EFFICAS studies

Medidata Solutions introduces Grants Manager 3.0 to select correct procedure for budgeting in trial

Medidata Solutions introduces Grants Manager 3.0 to select correct procedure for budgeting in trial

CAMD releases first combined clinical trial data on neuro-degenerative diseases

CAMD releases first combined clinical trial data on neuro-degenerative diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.